Zachariah McIver, D.O., Ph.D., is a distinguished physician-scientist with over two decades of experience in oncology and immunotherapy drug development. He earned his Doctor of Osteopathic Medicine from the Philadelphia College of Osteopathic Medicine and a Ph.D. in Pharmacology from the University of Pennsylvania, where his dissertation focused on novel T-cell activation mechanisms. Early in his career, Dr. McIver completed a residency in Internal Medicine at Johns Hopkins Hospital and a fellowship in Hematology-Oncology at the MD Anderson Cancer Center, honing his expertise in translational research and clinical trial design. As Former Chief Medical Officer at Janux Therapeutics Inc., Dr. McIver played a pivotal role in advancing the company's TRACTr platform, a suite of tumor-activated T-cell engagers targeting solid tumors. Under his leadership from 2020 to 2023, Janux progressed multiple candidates into Phase 1 clinical trials, achieving key milestones such as FDA clearance for JANX007 and the publication of preclinical data in high-impact journals like Nature Cancer. His strategic oversight ensured robust safety profiles and accelerated enrollment, positioning Janux as a leader in next-generation immunotherapies. Dr. McIver's achievements include authoring over 50 peer-reviewed publications, securing 12 patents in bispecific antibody technologies, and previously serving as VP of Clinical Development at Amgen, where he contributed to the approval of two blockbuster oncology drugs. Now consulting for emerging biotechs, he continues to mentor the next generation of clinician-scientists, emphasizing patient-centric innovation in precision medicine.